**Medi-MIBI 500 micrograms (99mTc-MIBI)**

**Tc-MR-1**

**Active substance**
- Sestamibi (Cu(MIBI)$_4$BF$_4$) 0.50 mg

**Indications**
- diagnosis of ischemic heart disease
- diagnosis and localization of myocardial infarction
- as diagnostic agent for the assessment of global ventricular function (left ventricular ejection fraction and/or wall motion)
- as second line diagnostic agent after mammography to assist in the evaluation of breast lesions in patients with abnormal X-ray mammograms or palpable breast mass, or as evidenced by other diagnostic procedures
- as diagnostic aid for detection and localisation of abnormal parathyroid tissue in patients with recurrent or persistent hyperparathyroidism and patients scheduled to undergo surgery of parathyroid glands (for detailed information see SmPC)

**Excipients**
- Stannous(II) chloride dihydrate
- Sodium chloride
- Tetrasodium pyrophosphate decahydrate
- L-cysteine hydrochloride monohydrate
- Glycine

**Dose for adults**
- Suggested dose ranges for i.v. administration to patient of average weight (70 kg) for
  - diagnosis for reduced coronary perfusion and myocardial infarction: 400-900 MBq
  - assessment of global ventricular function: 600-800 MBq (bolus)
  - diagnosis of ischemic heart disease: one-day-protocol: 400-500 MBq
    two-day-protocol: 600-900 MBq/study
  - breast imaging: 740-925 MBq (bolus)
  - parathyroid imaging: 185-740 MBq (bolus) (for detailed information see SmPC)

**Labelling activity**
- Up to 15 GBq

**Labelling volume**
- 1-5 ml

**Storage of cold kit**
- 30 months from date of manufacturing, below 25ºC protected from light

**Storage of labelled compound**
- 8 hrs below 25ºC

**Package size**
- 6 vials/kit
- Sample pack: 2 vials
- Bundle pack of 2x6 vials
- Bundle pack of 4x6 vials

**Registration numbers**
- Denmark: DK.R.2236
- Austria: 4-00035
- Germany: 68779.00.00
- Spain: 70755 OH
- Italy: 040312011/M

**Marketing Authorization Holder**
- Medi-Radiopharma Co., Ltd.
  2030 Érd, Szamos utca 10-12., Hungary